Francesco Dotta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9549839/publications.pdf

Version: 2024-02-01

217 papers

12,611 citations

³⁸⁷²⁰ 50 h-index

27389 106 g-index

228 all docs 228 docs citations

times ranked

228

13847 citing authors

#	Article	IF	CITATIONS
1	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	6.3	1,179
2	Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. Journal of Experimental Medicine, 2012, 209, 51-60.	4.2	572
3	Prolonged Exposure to Free Fatty Acids Has Cytostatic and Pro-Apoptotic Effects on Human Pancreatic Islets: Evidence that Â-Cell Death Is Caspase Mediated, Partially Dependent on Ceramide Pathway, and Bcl-2 Regulated. Diabetes, 2002, 51, 1437-1442.	0.3	547
4	NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1. Transplantation, 2003, 75, SS3-SS24.	0.5	547
5	Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5115-5120.	3.3	521
6	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 2018, 41, 258-266.	4.3	350
7	Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia, 2005, 48, 1565-1575.	2.9	309
8	Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia, 2005, 48, 2206-2212.	2.9	294
9	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	5.5	244
10	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	5.5	231
11	Guidelines for the treatment and management of new-onset diabetes after transplantation1 Clinical Transplantation, 2005, 19, 291-298.	0.8	228
12	Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1737-1744.	1.8	222
13	A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia, 2012, 55, 3262-3272.	2.9	208
14	High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes. Diabetes Care, 2007, 30, 932-938.	4.3	206
15	Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia, 2010, 53, 1395-1405.	2.9	200
16	Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic \hat{l}^2 Cell Death and May Contribute to Type 1 Diabetes Development. Cell Metabolism, 2019, 29, 348-361.e6.	7.2	200
17	CD4+CD25high regulatory T cells in human autoimmune diabetes. Journal of Autoimmunity, 2005, 24, 55-62.	3.0	181
18	Reduction of Circulating Neutrophils Precedes and Accompanies Type 1 Diabetes. Diabetes, 2013, 62, 2072-2077.	0.3	177

#	Article	IF	Citations
19	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559.	4.3	177
20	Conventional and Neo-antigenic Peptides Presented by \hat{l}^2 Cells Are Targeted by Circulating Na \tilde{A} -ve CD8+ T Cells in Type 1 Diabetic and Healthy Donors. Cell Metabolism, 2018, 28, 946-960.e6.	7.2	177
21	Islet-reactive CD8 ⁺ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Science Immunology, 2018, 3, .	5. 6	171
22	Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. Journal of Clinical Investigation, 2012, 122, 1717-1725.	3.9	168
23	Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatmentâ€naive patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2009, 11, 506-515.	2.2	164
24	Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes Journal of Experimental Medicine, 1992, 176, 67-77.	4.2	162
25	Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clinical and Experimental Immunology, 2010, 159, 338-343.	1.1	161
26	Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24â€week, randomized, doubleâ€blind study*. Diabetes, Obesity and Metabolism, 2008, 10, 82-90.	2.2	157
27	SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic \hat{l}^2 -Cells and in the Human Pancreas Microvasculature. Frontiers in Endocrinology, 2020, 11, 596898.	1.5	144
28	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet, The, 2012, 379, 2270-2278.	6.3	138
29	Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by <i>Lactococcus lactis</i> Reverses Diabetes in Recent-Onset NOD Mice. Diabetes, 2014, 63, 2876-2887.	0.3	129
30	MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetologica, 2015, 52, 523-530.	1.2	127
31	Increased expression of microRNA miRâ€326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes/Metabolism Research and Reviews, 2011, 27, 862-866.	1.7	116
32	Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia, 2008, 51, 1296-1305.	2.9	111
33	Endocrine Actions of Osteocalcin. International Journal of Endocrinology, 2013, 2013, 1-10.	0.6	105
34	Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes, Obesity and Metabolism, 2009, 11 , $589-595$.	2.2	100
35	An overview of pancreatic beta-cell defects in human type 2 diabetes: Implications for treatment. Regulatory Peptides, 2008, 146, 4-11.	1.9	99
36	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. International Journal of Molecular Sciences, 2019, 20, 3264.	1.8	93

#	Article	IF	CITATIONS
37	Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 683-690.	1.1	92
38	Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. Journal of Cellular Physiology, 2004, 200, 177-200.	2.0	89
39	Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. Cell Death and Differentiation, 2007, 14, 1860-1871.	5.0	89
40	MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic \hat{l}^2 -Cells. Diabetes, 2017, 66, 100-112.	0.3	87
41	Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight, 2018, 3, .	2.3	85
42	Italian Addison Network Study: Update of Diagnostic Criteria for the Etiological Classification of Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1598-1604.	1.8	83
43	MicroRNAs as Regulators of Insulin Signaling: Research Updates and Potential Therapeutic Perspectives in Type 2 Diabetes. International Journal of Molecular Sciences, 2018, 19, 3705.	1.8	77
44	Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?. Journal of Endocrinological Investigation, 2017, 40, 591-610.	1.8	72
45	Dietary Supplementation With High Doses of Regular Vitamin D3 Safely Reduces Diabetes Incidence in NOD Mice When Given Early and Long Term. Diabetes, 2014, 63, 2026-2036.	0.3	66
46	Circulating microRNA (miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of miRNA miR-330-3p. Frontiers in Endocrinology, 2017, 8, 345.	1.5	65
47	Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia, 2018, 61, 2344-2355.	2.9	60
48	Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10–Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. Diabetes, 2017, 66, 448-459.	0.3	57
49	Identification of Tyrosine Phosphatase 2(256–760) Construct as a New, Sensitive Marker for the Detection of Islet Autoimmunity in Type 2 Diabetic Patients. Diabetes, 2008, 57, 1276-1283.	0.3	53
50	Circulating miRNA95 and miRNA190 Are Sensitive Markers for the Differential Diagnosis of Thyroid Nodules in a Caucasian Population. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4190-4198.	1.8	53
51	Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. Scientific Reports, 2017, 7, 6897.	1.6	53
52	Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes and Metabolism, 2017, 43, 512-520.	1.4	51
53	MicroRNAs: Novel Players in the Dialogue between Pancreatic Islets and Immune System in Autoimmune Diabetes. BioMed Research International, 2015, 2015, 1-11.	0.9	50
54	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetologica, 2019, 56, 605-617.	1.2	50

#	Article	IF	CITATIONS
55	Th2 Cytokines Have a Partial, Direct Protective Effect on the Function and Survival of Isolated Human Islets Exposed to Combined Proinflammatory and Th1 Cytokines. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4974-4978.	1.8	49
56	Circulating MicroRNAs as Biomarkers of Gestational Diabetes Mellitus: Updates and Perspectives. International Journal of Endocrinology, 2018, 2018, 1-11.	0.6	49
57	Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled studyâ€"the D.A.N.T.E (Diabetic ulcer Antimicrobial New) Tj ETQq1 I	l Ω 2⁄784314	44 % BT/Ove
58	IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets. Diabetologia, 2014, 57, 502-511.	2.9	47
59	Ganglioside Expression in Human Pancreatic Islets. Diabetes, 1989, 38, 1478-1483.	0.3	46
60	Mast cells infiltrate pancreatic islets in human type 1 diabetes. Diabetologia, 2015, 58, 2554-2562.	2.9	46
61	Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. European Journal of Endocrinology, 1999, 141, 644-652.	1.9	44
62	Function of pancreatic islets isolated from a type 1 diabetic patient. Diabetes Care, 2000, 23, 701-703.	4.3	43
63	Innate immunity and the pathogenesis of type 1 diabetes. Seminars in Immunopathology, 2011, 33, 57-66.	2.8	40
64	The social burden of hypoglycemia in the elderly. Acta Diabetologica, 2015, 52, 677-685.	1.2	40
65	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovascular Diabetology, 2015, 14, 116.	2.7	39
66	Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism. Non-coding RNA, 2018, 4, 37.	1.3	39
67	Gangliosides and autoimmune diabetes. , 1997, 13, 163-179.		37
68	Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism. Frontiers in Endocrinology, 2013, 4, 73.	1.5	36
69	MicroRNA expression profiles of human iPSCs differentiation into insulin-producing cells. Acta Diabetologica, 2017, 54, 265-281.	1.2	36
70	Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. European Journal of Endocrinology, 2010, 162, 361-369.	1.9	35
71	Expression of Cytoplasmic Islet Cell Antigens by Rat Pancreas. Diabetes, 1987, 36, 982-985.	0.3	34
72	GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. Diabetologia, 1995, 38, 1117-1121.	2.9	34

#	Article	IF	CITATIONS
73	Analysis of Posttransplant Diabetes Mellitus Prevalence in a Population of Kidney Transplant Recipients. Transplantation Proceedings, 2008, 40, 1888-1890.	0.3	34
74	Human induced pluripotent stem cells differentiate into insulin-producing cells able to engraft in vivo. Acta Diabetologica, 2015, 52, 1025-1035.	1.2	33
75	Circulating MicroRNAs in Elderly Type 2 Diabetic Patients. International Journal of Endocrinology, 2018, 2018, 1-11.	0.6	32
76	Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. European Journal of Endocrinology, 2005, 152, 485-489.	1.9	31
77	Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. Clinical and Experimental Immunology, 2012, 168, 24-29.	1.1	31
78	Autoimmunity to the GM2-1 Islet Ganglioside Before and at the Onset of Type I Diabetes. Diabetes, 1996, 45, 1193-1196.	0.3	30
79	Prognostic bioindicators in severe COVID-19 patients. Cytokine, 2021, 141, 155455.	1.4	30
80	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. Journal of Cellular Biochemistry, 2002, 84, 636-644.	1.2	29
81	Tyrosine Phosphatase–Related Islet Antigen 2(256–760) Autoantibodies, the Only Marker of Islet Autoimmunity That Increases by Increasing the Degree of BMI in Obese Subjects With Type 2 Diabetes. Diabetes Care, 2015, 38, 513-520.	4.3	29
82	Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes. International Journal of Molecular Sciences, 2019, 20, 6358.	1.8	29
83	Measuring adrenal autoantibody response: Interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clinical Immunology, 2011, 140, 291-299.	1.4	27
84	Viral Infections and Diabetes. Advances in Experimental Medicine and Biology, 2013, 771, 252-271.	0.8	27
85	Impaired Caspase-3 Expression by Peripheral T Cells in Chronic Autoimmune Thyroiditis and in Autoimmune Polyendocrine Syndrome-2. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 5064-5068.	1.8	26
86	Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. Clinical and Experimental Immunology, 2011, 166, 317-324.	1.1	26
87	Rationale and design of the DARWIN-T2D (DApagliflozin Real World evideNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1089-1097.	1.1	26
88	BOVINE ISLETS ARE LESS SUSCEPTIBLE THAN HUMAN ISLETS TO DAMAGE BY HUMAN CYTOKINES1. Transplantation, 2001, 71, 21-26.	0.5	25
89	The case for virus-induced type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 292-298.	1.2	25
90	Immunology in diabetic pregnancy: activated T cells in diabetic mothers and neonates. Diabetologia, 1987, 30, 66-71.	2.9	24

#	Article	lF	CITATIONS
91	Determination of gangliosides by high-performance liquid chromatography with photodiode-array detection. Journal of Chromatography A, 1992, 605, 221-225.	1.8	24
92	Identification of a novel type 1 diabetes-specific epitope by screening phage libraries with sera from pre-diabetic patients. Journal of Molecular Biology, 1997, 268, 599-606.	2.0	24
93	The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. European Journal of Endocrinology, 2004, 151, 207-214.	1.9	24
94	Relative sensitivity of immunohistochemistry, multiple reaction monitoring mass spectrometry, in situ hybridization and PCR to detect Coxsackievirus B1 in A549 cells. Journal of Clinical Virology, 2016, 77, 21-28.	1.6	23
95	miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes. Diabetologia, 2020, 63, 124-136.	2.9	23
96	Extracellular Vesicles in Immune System Regulation and Type 1 Diabetes: Cell-to-Cell Communication Mediators, Disease Biomarkers, and Promising Therapeutic Tools. Frontiers in Immunology, 2021, 12, 682948.	2.2	23
97	Type I diabetes mellitus: A predictable autoimmune disease with interindividual variation in the rate of \hat{l}^2 cell destruction. Clinical Immunology and Immunopathology, 1989, 50, S85-S95.	2.1	22
98	Autoantibody negative new onset Type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these Type 1b diabetes cases?. Diabetes/Metabolism Research and Reviews, 2000, 16, 8-14.	1.7	22
99	Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus. European Journal of Endocrinology, 2005, 152, 119-125.	1.9	22
100	Prevention and treatment of autoimmune diseases with plant virus nanoparticles. Science Advances, 2020, 6, eaaz0295.	4.7	22
101	Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction Endocrinology, 1992, 130, 37-42.	1.4	21
102	Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. Journal of Endocrinology, 1996, 150, 113-120.	1.2	21
103	Autoantibodies to the GM2-1 Islet Ganglioside and to GAD-65 at Type 1 Diabetes Onset. Journal of Autoimmunity, 1997, 10, 585-588.	3.0	21
104	Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. Diabetes/Metabolism Research and Reviews, 2004, 20, 246-251.	1.7	21
105	Acute on chronic limb ischemia: From surgical embolectomy and thrombolysis to endovascular options. Seminars in Vascular Surgery, 2018, 31, 66-75.	1.1	21
106	Can NK cells be a therapeutic target in human type 1 diabetes?. European Journal of Immunology, 2008, 38, 2961-2963.	1.6	20
107	From immunohistological to anatomical alterations of human pancreas in type 1 diabetes: New concepts on the stage. Diabetes/Metabolism Research and Reviews, 2020, 36, e3264.	1.7	20
108	Selection of Phage-Displayed Peptides Mimicking Type 1 Diabetes-Specific Epitopes. Journal of Autoimmunity, 1996, 9, 431-436.	3.0	19

#	Article	IF	CITATIONS
109	MicroRNAs: markers of \hat{l}^2 -cell stress and autoimmunity. Current Opinion in Endocrinology, Diabetes and Obesity, 2018, 25, 237-245.	1.2	19
110	Intestinal Delivery of Proinsulin and IL-10 via Lactococcus lactis Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis. Frontiers in Immunology, 2020, 11, 1103.	2.2	19
111	MicroRNA profiling in sera of patients with type 2 diabetes mellitus reveals an upregulation of miR-31 expression in subjects with microvascular complications. Journal of Biomedical Science and Engineering, 2013, 06, 58-64.	0.2	18
112	Identification and Validation of miR-222-3p and miR-409-3p as Plasma Biomarkers in Gestational Diabetes Mellitus Sharing Validated Target Genes Involved in Metabolic Homeostasis. International Journal of Molecular Sciences, 2022, 23, 4276.	1.8	18
113	The GM2-1 Ganglioside Islet Autoantigen in Insulin-Dependent Diabetes Mellitus Is Expressed in Secretory Granules and Is $Notl^2$ -Cell Specific*. Endocrinology, 1998, 139, 316-319.	1.4	17
114	Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1 Diabetes. Frontiers in Endocrinology, 2020, 11, 630.	1.5	17
115	Rat Pancreatic Ganglioside Expression: Differences between a Model of Autoimmune Islet B Cell Destruction and a Normal Strain. Clinical Immunology and Immunopathology, 1993, 66, 143-149.	2.1	16
116	Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512bdc dominant autoantigenic epitopes. European Journal of Immunology, 2002, 32, 1420.	1.6	16
117	IA-2 combined epitope assay: A new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes. Clinical Immunology, 2005, 115, 260-267.	1.4	16
118	Circulating Anti-Immunoglobulin Antibodies in Recent-Onset Type I Diabetic Patients. Diabetes, 1988, 37, 462-466.	0.3	15
119	Congenital Autoimmune Diabetes Mellitus. New England Journal of Medicine, 2000, 342, 1529-1531.	13.9	15
120	Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. International Journal of Molecular Sciences, 2021, 22, 7716.	1.8	15
121	T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. European Journal of Endocrinology, 1999, 141, 272-278.	1.9	14
122	Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2012, 13, 1377-1384.	0.9	14
123	Erectile dysfunction and diabetes: Association with the impairment of lipid metabolism and oxidative stress. Clinical Biochemistry, 2016, 49, 70-78.	0.8	14
124	MicroRNA Expression Analysis of In Vitro Dedifferentiated Human Pancreatic Islet Cells Reveals the Activation of the Pluripotency-Related MicroRNA Cluster miR-302s. International Journal of Molecular Sciences, 2018, 19, 1170.	1.8	14
125	MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema. International Journal of Molecular Sciences, 2020, 21, 7328.	1.8	14
126	Anti-Ganglioside Antibodies in New Onset Type 1 Diabetic Patients and High Risk Subjects. Autoimmunity, 1995, 22, 43-48.	1.2	13

#	Article	IF	CITATIONS
127	Virus Infections: Lessons from Pancreas Histology. Current Diabetes Reports, 2010, 10, 357-361.	1.7	13
128	Enteroviral Infections and Development of Type 1 Diabetes: The Brothers Karamazov Within the CVBs. Diabetes, 2014, 63, 384-386.	0.3	13
129	Fostering improved human islet research: a European perspective. Diabetologia, 2019, 62, 1514-1516.	2.9	13
130	MicroRNAs as New Tools for Exploring Type 1 Diabetes: Relevance for Immunomodulation and Transplantation Therapy. Transplantation Proceedings, 2011, 43, 330-332.	0.3	12
131	G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 201-213.	2.2	12
132	Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. Scandinavian Journal of Immunology, 2021, 94, e13031.	1.3	12
133	Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study. International Journal of Molecular Sciences, 2021, 22, 9454.	1.8	12
134	Incretin hormones and beta-cell mass expansion: what we know and what is missing?. Archives of Physiology and Biochemistry, 2013, 119, 161-169.	1.0	11
135	Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?. Current Diabetes Reports, 2015, 15, 115.	1.7	11
136	The Landscape of microRNAs in \hat{I}^2 Cell: Between Phenotype Maintenance and Protection. International Journal of Molecular Sciences, 2021, 22, 803.	1.8	11
137	CD8+ T cells variably recognize native versus citrullinated GRP78 epitopes in type 1 diabetes. Diabetes, 2021, 70, db210259.	0.3	11
138	ICA512(IA-2) Epitope Specific Assays Distinguish Transient from Diabetes Associated Autoantibodies. Journal of Autoimmunity, 2002, 18, 191-196.	3.0	10
139	The acquisition of an insulin-secreting phenotype by HGF-treated rat pancreatic ductal cells (ARIP) is associated with the development of susceptibility to cytokine-induced apoptosis. Journal of Molecular Endocrinology, 2005, 34, 367-376.	1.1	10
140	Serum transforming growth factor \hat{l}^21 during diabetes development in non-obese diabetic mice and humans. Clinical and Experimental Immunology, 2010, 162, 407-414.	1.1	10
141	Dual energy CT in gland tumors: a comprehensive narrative review and differential diagnosis. Gland Surgery, 2020, 9, 2269-2282.	0.5	10
142	Expression of cytoplasmic islet cell antigens by rat pancreas. Diabetes, 1987, 36, 982-985.	0.3	10
143	Ganglioside expression in human pancreatic islets. Diabetes, 1989, 38, 1478-1483.	0.3	10
144	Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type I diabetes. Diabetes, 1996, 45, 1193-1196.	0.3	10

#	Article	IF	Citations
145	Circulating microRNAs as clinically useful biomarkers for Type 2 Diabetes Mellitus: miRNomics from bench to bedside. Translational Research, 2022, 247, 137-157.	2.2	10
146	Insulin Prophylaxis Down-regulates Islet Antigen Expression and Islet Autoimmunity in the Low-dose Stz Mouse Model of Diabetes. Autoimmunity, 1999, 29, 249-256.	1.2	9
147	Long-standing type 1 diabetes: patients with adult-onset develop celiac-specific immunoreactivity more frequently than patients with childhood-onset diabetes, in a disease duration-dependent manner. Acta Diabetologica, 2014, 51, 675-678.	1.2	9
148	Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Research and Clinical Practice, 2016, 120, S51.	1.1	9
149	Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study. BMC Medicine, 2019, 17, 83.	2.3	9
150	Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology. International Journal of Molecular Sciences, 2020, 21, 1270.	1.8	9
151	Increased Expression of Viral Sensor MDA5 in Pancreatic Islets and in Hormone-Negative Endocrine Cells in Recent Onset Type 1 Diabetic Donors. Frontiers in Immunology, 2022, 13, 833141.	2.2	9
152	The autonomic innervation of the human greater saphenous vein. Acta Histochemica, 1983, 72, 111-116.	0.9	8
153	Activated T cells in normal pregnant women and neonates. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1986, 23, 127-135.	0.5	8
154	A Novel Neuroendocrine Cell Surface Glycoprotein: Identification, Isolation, and Initial Characterization*. Endocrinology, 1988, 122, 1263-1268.	1.4	8
155	Antigenic determinants in type 1 diabetes mellitus:. Apmis, 1996, 104, 769-774.	0.9	8
156	Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. Clinical Immunology, 2003, 109, 318-324.	1.4	8
157	Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al Diabetes, Obesity and Metabolism, 2010, 12, 1127-1128.	2.2	8
158	Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: A case report. Islets, 2011, 3, 231-233.	0.9	8
159	The Year in Immune Intervention for Type 1 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, S-88-S-95.	2.4	8
160	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. Journal of Cellular Biochemistry, 2002, 84, 636-44.	1.2	8
161	Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells. Frontiers in Oncology, 0, 12, .	1.3	8
162	Autoantigens in Thyroid and Islet Autoimmunity: Similarities and Differences. Autoimmunity, 1992, 12, 223-237.	1,2	7

#	Article	IF	CITATIONS
163	Effects of prolonged exposure to pancreatic glucagon on the function, antigenicity and survival of isolated human islets. Diabetes/Metabolism Research and Reviews, 2000, 16, 281-286.	1.7	7
164	Neonatal syndromes of polyendocrinopathy. Endocrinology and Metabolism Clinics of North America, 2002, 31, 283-293.	1.2	7
165	Deltaâ€eellâ€specific expression of hedgehog pathway Ptch1 receptor in murine and human endocrine pancreas. Diabetes/Metabolism Research and Reviews, 2011, 27, 755-760.	1.7	7
166	In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. Acta Diabetologica, 2012, 49, 123-131.	1.2	7
167	Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples. STAR Protocols, 2021, 2, 100606.	0.5	7
168	A prozone phenomenon interferes in islet cell antibody detection: Direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. Journal of Autoimmunity, 1988, 1, 109-117.	3.0	6
169	Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. Diabetes/metabolism Reviews, 1993, 9, 245-249.	0.4	6
170	Presence of Interleukin 4 or Interleukin 10, but Not Both Cytokines, in Pancreatic Tissue of Two Patients with Recently Diagnosed Diabetes Mellitus Type I. Autoimmunity, 2000, 32, 161-166.	1.2	6
171	Diagnosis and approach to posttransplant diabetes. Current Diabetes Reports, 2009, 9, 317-323.	1.7	6
172	Putative endothelial progenitor cells predict long-term mortality in type-2 diabetes. Endocrine, 2018, 62, 263-266.	1.1	6
173	Circulating anti-immunoglobulin antibodies in recent-onset type I diabetic patients. Diabetes, 1988, 37, 462-466.	0.3	6
174	Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology 2.0. International Journal of Molecular Sciences, 2022, 23, 6831.	1.8	6
175	β-cell autoimmunity 1998. , 1998, 14, 1-2.		5
176	Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. Annals of Clinical Biochemistry, 2008, 45, 218-220.	0.8	5
177	Fighting diabetic foot ulcers—The diabetologist: A king maker of the fight. Seminars in Vascular Surgery, 2018, 31, 49-55.	1.1	5
178	Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction , 0 , .		5
179	Humoral and Cellular Immune Abnormalities in Neonates of Diabetic Mothers: Any Pathological Role?. Experimental and Clinical Endocrinology and Diabetes, 1987, 89, 333-339.	0.6	4
180	Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: A new tool to distinguish disease-specific immunoreactivities. Clinical Immunology, 2006, 121, 40-46.	1.4	4

#	Article	IF	CITATIONS
181	GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva. Clinical Immunology, 2009, 131, 271-276.	1.4	4
182	Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective <scp>E</scp> uropean <scp>E</scp> xenatide (<scp>EUREXA</scp>) study. Diabetes, Obesity and Metabolism, 2015, 17, 689-698.	2.2	4
183	Immunoregulated insulitis and slow-progressing type 1 diabetes after duodenopancreatectomy. Diabetologia, 2021, 64, 2731-2740.	2.9	4
184	Type 1 diabetes mellitus as a polygenic multifactorial disease: immunopathogenic mechanisms of beta-cell destruction. Acta Biomedica, 2005, 76 Suppl 3, 14-8.	0.2	4
185	Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II. International Journal of Environmental Research and Public Health, 2022, 19, 2176.	1.2	4
186	NF- \hat{l}^2 B-inducing kinase (NIK) is activated in pancreatic \hat{l}^2 -cells but does not contribute to the development of diabetes. Cell Death and Disease, 2022, 13, 476.	2.7	4
187	A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. Journal of Immunological Methods, 1997, 207, 107-113.	0.6	3
188	Comment on: Meagher et al. Neutralization of Interleukin-16 Protects Nonobese Diabetic Mice From Autoimmune Type 1 Diabetes by a CCL4-Dependent Mechanism. Diabetes 2010;59:2862-2871. Diabetes, 2011, 60, e12-e12.	0.3	3
189	Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3). Canadian Journal of Diabetes, 2016, 40, S41.	0.4	3
190	Autoantigens in type 1 diabetes mellitus. Journal of Endocrinological Investigation, 1994, 17, 497-508.	1.8	2
191	Type VII collagen in Alport syndrome. Nephrology Dialysis Transplantation, 2007, 22, 3501-3507.	0.4	2
192	Hedgehog Signaling during Expansion of Human Pancreatic Isletâ€Derived Precursors. Annals of the New York Academy of Sciences, 2008, 1150, 43-45.	1.8	2
193	In Type 1 Diabetes Immunocompetent Cells are Defective in ILâ€16 Secretion. Scandinavian Journal of Immunology, 2012, 75, 127-128.	1.3	2
194	Autoantibody negative new onset Type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these Type 1b diabetes cases?. Diabetes/Metabolism Research and Reviews, 2000, 16, 8-14.	1.7	2
195	Micro-RNA expression profiling in Paget's disease of bone. Bone Abstracts, 0, , .	0.0	2
196	Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment. Biomedicines, 2022, 10, 761.	1.4	2
197	Pancreatic Gangliosides Delay the Onset of Insulitis and Hyperglycaemia in the Low-Dose Streptozotocin Mouse Model. Scandinavian Journal of Immunology, 1993, 37, 308-313.	1.3	1
198	Gangliosides and autoimmune diabetes. Diabetes/metabolism Reviews, 1997, 13, 163-179.	0.4	1

#	Article	IF	Citations
199	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. Journal of Cellular Biochemistry, 2002, 84, 636.	1.2	1
200	Assay for Cytoplasmic Islet Cell Antibodies Using Two-Color Immunofluorescence and Rat Pancreas. Advances in Experimental Medicine and Biology, 1988, 246, 63-69.	0.8	1
201	Type I Diabetes as a "Mendelian―and "Regulated―lmmune Process. , 1990, , 351-362.		1
202	The Use of Immunological Markers in IDDM After More Than 20 Years From ICA Description. Diabetes/metabolism Reviews, 1996, 12, 121-126.	0.4	1
203	GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. Diabetologia, 1995, 38, 1117-1121.	2.9	1
204	Pathological changes in human insulitis. Current Opinion in Endocrinology, Diabetes and Obesity, 2004, 11, 82-84.	0.6	0
205	Incretine e funzione insulare: fisiopatologia. L Endocrinologo, 2008, 9, 155-162.	0.0	0
206	POST TRANSPLANTATION DIABETES MELLITUS: ROLE OF INSULIN-RESISTANCE AND PRO-INFLAMMATORY CYTOKINES IN FIRST YEAR POST-TRANSPLANT. Transplantation, 2008, 86, 275.	0.5	0
207	Coxsackieviruses and Insulitis. , 2013, , 157-166.		0
208	The map of diabetes and its determinants within the metropolitan area of Rome. European Journal of Public Health, 2017, 27, .	0.1	0
209	Rome as a walkable city for reduce the impact of the Obesity, T2DM and CDV risks. European Journal of Public Health, $2018, 28, .$	0.1	0
210	Urban health in Italy: health outcomes and sustainable living. European Journal of Public Health, 2018, 28, .	0.1	0
211	Combination of serum miRNA-190 and -95 is a powerful non-invasive tool in the differential diagnosis of thyroid nodules: preliminary data of a prospective series. Endocrine Abstracts, 0 , , .	0.0	0
212	Clinical and experimental evidence suggest a protective effect of Paget's disease of bone against skeletal metastasization from solid tumors. Bone Abstracts, 0, , .	0.0	0
213	FGF23 and SCL are expressed in carotid plaques and the association between their circulating fractions and fractures differs in relation to comorbidity in elderly individuals. Bone Abstracts, 0, , .	0.0	0
214	FGF23 and SCL are expressed in carotid plaques and the association between their circulating fractions and fractures differs in relation to comorbidity in elderly individuals. Bone Abstracts, 0, , .	0.0	0
215	Selective expresssion of one specific isoform of the coxsackie adenovirus receptor (CAR) in the human pancreatic beta cells. Endocrine Abstracts, 0, , .	0.0	0
216	1795-P: Proinsulin-Insulin Pancreatic Islets In-situ Expression Mirrors Metabolic Defects Observed in Type 2 Diabetic and Glucose Intolerant Living Donors. Diabetes, 2020, 69, 1795-P.	0.3	0

 #	Article	IF	CITATIONS
217	Urban diabetes: the case of the metropolitan area of Rome. European Journal of Public Health, 2018, 28,	0.1	0